Ignite Creation Date:
2024-05-06 @ 2:00 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04182724
Status:
UNKNOWN
Last Update Posted:
2019-12-03
First Post:
2019-11-27
Brief Title:
Camrelizumab Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Organization Data
Organization:
Chinese PLA General Hospital
Class:
OTHER
Study ID:
Camrelizumab GC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Chinese PLA General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Dai Guanghai
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Chinese PLA General Hospital
Old Name:
None
Old Organization:
None